A Phase 1 interventional study of Staccato Alprazolam and Midazolam in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants who successfully completed the Screening Period will receive single dose of Intravenous (IV) midazolam on Day 1 of the Intervention Period.
Drug: Midazolam
Study participants randomized in Group 1 will receive Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 1 followed by Treatment B: IV Midazolam on Day 1 of the Intervention Period 2.
Drug: Staccato Alprazolam · Drug: Midazolam
Study participants randomized in Group 1 will receive Treatment B: IV Midazolam on Day 1 of the Intervention Period 1 followed by Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 2.
Drug: Staccato Alprazolam · Drug: Midazolam
Study participants randomized in Group 2 will receive Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 1 followed by Treatment C: Nasal Diazepam on Day 1 of the Intervention Period 2.
Drug: Staccato Alprazolam · Drug: Diazepam
Study participants randomized in Group 2 will receive Treatment C: Nasal Diazepam on Day 1 of the Intervention Period 1 followed by Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 2.
Drug: Staccato Alprazolam · Drug: Diazepam
Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.
Also known as: UCB7538
Study participants will receive single dose of IV Midazolam at pre-specified time points.
Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.
Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of Staccato alprazolam in Group 1
Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the quantitative electroencephalogram (qEEG) data recorded for each study participant.
Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1
Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of iv midazolam in Group 1
Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the quantitative electroencephalogram (qEEG) data recorded for each study participant.
Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1
Occurrence of Treatment Emergent Adverse Events (TEAEs) from the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV)
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment.
Time frame: From the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV) (up to 55 Days)
Occurrence of Serious TEAEs from the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV)
Serious Treatment-Emergent Adverse Events (Serious TEAEs) are any untoward medical incidence in a participant during administered study treatment, whether or not these events are related to study treatment and additionally are emergent untoward medical occurrence that at any dose: Results in death; Is life-threatening; Requires in patient hospitalisation or prolongation of existing hospitalisation; Results in persistent disability/incapacity; Is a congenital anomaly or birth defect; Important medical events.
Time frame: From the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV) (up to 55 Days)
Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 Minutes of study intervention administration of Staccato alprazolam in Group 2
Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the qEEG data recorded for each study participant.
Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 2
Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 Minutes of study intervention administration of nasal diazepam in Group 2
Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the qEEG data recorded for each study participant.
Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 2
Maximum concentration (Cmax) of alprazolam
Cmax=maximum concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of alprazolam
AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of alprazolam
AUC=area under the concentration-time curve from time 0 to infinity
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Maximum concentration (Cmax) of midazolam
Cmax=maximum concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of midazolam
AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of midazolam
AUC=area under the concentration-time curve from time 0 to infinity
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Maximum concentration (Cmax) of diazepam
Cmax=maximum concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of diazepam
AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of diazepam
AUC=area under the concentration-time curve from time 0 to infinity
Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose
Plan to share: No — Due to the small sample size in this trial, individual patient-level data (IPD) cannot be adequately anonymized as, there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jan 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alprazolam · Midazolam · Diazepam